Event Date: Jun 20, 2019
High cholesterol, high blood pressure, and diabetes are not only risk factors for cardiovascular disease, but they can also have significant contributions to dementia risk.
This webinar will discuss the vascular system in the brain and present new research findings that maintaining good cardiovascular health may be an important strategy to delay the onset of dementia or slow its progression.
Dr. Cheryl Wellington, Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia.
Dr. Cheryl Wellington is a Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. Dr. Wellington’s research interests focus on dementia, traumatic brain injury, cerebrovascular dysfunction, and lipoprotein metabolism, in humans, animal models, and engineered human tissues.
Dr. Wellington developed the first perfusible bioengineered model of the human blood brain barrier and large cerebral vessels. She also co-founded the CHIMERA (Closed Head Impact Model of Engineered Rotational Acceleration) platform of TBI animal modeling, which a unique system that uses non-surgical methods to deliver precise mechanical inputs to an unconstrained head and is now recognized as an excellent model of mild TBI and concussion.
Dr. Wellington has published over 120 papers, trained over 35 junior scientists in a dynamic multidisciplinary environment, and has contributed to workshops held by National Institutes of Neurological Disorders and Stroke, National Heart Lung and Blood Institute, Alzheimer’s Association, and the Canadian Institutes of Health Research on dementia. She is a Team Leader within the Canadian Consortium for Neurodegeneration in Aging, Canada’s lead basic scientist in the Biomarkers Working Group of the International Traumatic Brain Injury Research Consortium, and Co-Principal Investigator in the Canadian Traumatic Brain Injury Research Consortium. Her studies have supported by the Canadian Institutes of Health Research, Weston Brain Institute, BrightFocus, Alzheimer Society of Canada, the Heart and Stroke Foundation of Canada, Alzheimer’s Drug Discovery Foundation, Pfizer, and AstraZeneca.